News

NBC Los Angeles7h
Novo Nordisk cuts 2025 guidance as drug copycats hit Wegovy sales, posts first-quarter profit beat
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
How copycats of Wegovy, Zepbound created a billion-dollar market
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
Novo Nordisk Forges Multiple Partnerships To Sell Obesity Drug Wegovy At A Discount
The pharmaceutical firm Novo Nordisk is pursuing a multipronged strategy to regain market share that it has lost to Eli Lilly ...
Novo Nordisk teams with telehealth firms Hims, Ro to sell Wegovy at lower price
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
pharmaphorum4d
Lilly hit as PBM drops Zepbound, but retains Wegovy
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...
Healthcare Dive5d
CVS plans to exit ACA individual exchanges, strikes Wegovy deal with Novo Nordisk
Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...